Regulatory roles of galectins on influenza A virus and their potential as a therapeutic strategy

• Main Authors: Zih-Syuan Yang, Chih-Yen Lin, Szu-Wei Huang, Wen-Hung Wang, Aspiro Nayim Urbina, Sung-Pin Tseng, Po-Liang Lu, Yen-Hsu Chen, Sheng-Fan Wang
• Format: Article
• Language: English
• Published: Elsevier 2021-07-01
• Series: Biomedicine & Pharmacotherapy
• Subjects: Galectins; Influenza A virus; Therapeutic agent; Review; PRISMA
• Online Access: http://www.sciencedirect.com/science/article/pii/S0753332221004959

Galectins, are β-galactoside binding lectins expressed in numerous cells and are known to regulate various immune responses and cellular physiological functions. Galectins have been reported to participate in the regulation of several viral infections via carbohydrate‑dependent/independent manner. Galectins have displayed various regulatory functions on viral infection, however, the detailed mechanism remains unclear. More recently, some members of galectins have been reported to regulate influenza A virus (IAV) infection. In this review, we aim to analyze and summarize current findings regarding the role of galectins in IAV infection and their antiviral potential therapeutic application in the treatment of IAVs. The eligible articles were selected according to the PRISMA guidelines. Results indicate that Galectin-1(Gal-1), Galectin-3(Gal-3) and Galectin-9 (Gal-9) were found as the predominant galectins reported to participate in the regulation of IAVs infection. The inhibitory regulation of IAVs by these galectins occurred mainly through extracellular binding to glycosylated envelope proteins, further blocking the interaction between influenza envelope and sialic acid receptor, interacting with ligands or receptors on immune cells to trigger immunol or cellular response against IAVs, and endogenously interacting cellular components in the cytoplasm to activate inflammasome and autophagy. This study offers information regarding the multiple roles of galectins observed in IAVs infection and suggest that galectins has the potential to be used as therapeutic agents for IAVs.